Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates |
| |
| Authors: | Bergamo A Gaiddon C Schellens J H M Beijnen J H Sava G |
| |
| Affiliation: | a Callerio Foundation Onlus, Via A. Fleming 22-31, 34127 Trieste, Italyb University of Strasbourg, UMRS692 INSERM, 11 rue Human, 67085, Strasbourg, Francec Netherlands Cancer Institute, Amsterdam, The Netherlandsd Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlandse University of Trieste, Department of Life Sciences, via L. Giorgieri 7, 34127 Trieste, Italy |
| |
| Abstract: | The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development. |
| |
| Keywords: | Platinum Ruthenium Tumour Therapy Drug Mechanism of action |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
